Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
13.54
+0.28 (2.11%)
Nov 4, 2024, 4:00 PM EST - Market closed
Avalo Therapeutics Employees
Avalo Therapeutics had 19 employees as of December 31, 2023. The number of employees decreased by 1 or -5.00% compared to the previous year.
Employees
19
Change (1Y)
-1
Growth (1Y)
-5.00%
Revenue / Employee
$42,474
Profits / Employee
-$1,906,474
Market Cap
131.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
23andMe Holding Co. | 582 |
Akoya Biosciences | 330 |
Seer, Inc. | 147 |
TriSalus Life Sciences | 112 |
Scilex Holding Company | 105 |
Fractyl Health | 102 |
Elutia | 54 |
Journey Medical | 41 |
AVTX News
- 27 days ago - Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 3 months ago - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - GlobeNewsWire
- 5 months ago - Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit - GlobeNewsWire
- 6 months ago - Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Avalo Therapeutics Appoints Biotech Leaders to Board of Directors - GlobeNewsWire
- 7 months ago - Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip? - Invezz